Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
Approval has been given for the first UK launch of a traditional "vertical" rocket. The critical clearance from the air safety regulator has taken the country a step closer to seeing its first ...
The licence for a vertical launch is the final authorisation needed to realise Britain’s decade-long ambition to become an independent spacefaring nation with its own privately developed ...
Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback